Vuse overtakes Juul in US convenience store sales

Oct.22.2022
Vuse overtakes Juul in US convenience store sales
Vuse's e-cigarette market share surpasses Juul's, reaching 12% in Nielsen's latest convenience store analysis.

According to Nielsen's latest analysis of convenience store data, the market share of Vuse brand electronic cigarettes has surpassed Juul and expanded to 12%.


As of October 8th, the market share of Vuse has increased from 39.7% reported earlier to 40%, while Juul's share has decreased from 28.1% to 28%.


Vuse has increased its year-on-year advantage from 32.9% in the previous report to a range of 32.7% to 33.6% to 32%. According to Barclays Bank, Nielsen mainly covers large chain stores. The organization inferred that this is why Nielsen did not immediately show a trend change for smaller chain stores, as reported by the Winston-Salem Journal.


In recent months, the shadow of a potential ban on Juul Labs Inc.'s electronic cigarettes in US retail shelves has accelerated Vuse's market share growth.


Meanwhile, NJoy, ranked third, held steady with 2.8%, while Fontem Ventures' blu eCigs also held steady at 1.4%.


Juul's four-week USD sales figures have dropped from 50.2% in the August 10, 2019 report to a current decrease of 18%, according to their latest report.


In comparison, Reynolds' Vuse increased by 42% in the latest report, while NJoy increased by 5.9%, and blu eCigs decreased by 30.9%.


Statement:


This article is compiled from third-party information and is intended for industry communication and learning purposes only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity or accuracy of the article's content. The translation of this article is solely intended for the purpose of industry communication and research.


Due to limitations in translation ability, the translated article may not fully accurately convey the original meaning. Please refer to the original article for an accurate representation.


2FIRSTS maintains complete alignment with the Chinese government in regards to any statements or positions related to domestic, Hong Kong, Macau, Taiwan, or foreign affairs.


The compilation of information is the property of the original media and author. If there is any infringement, please contact to request removal.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Malaysia health minister says court conviction over vape promotion sets key precedent for Act 852 enforcement
Malaysia health minister says court conviction over vape promotion sets key precedent for Act 852 enforcement
Malaysia’s Health Minister Datuk Seri Dr Dzulkefly Ahmad said the Putrajaya Magistrate’s Court decision to convict a known personality for promoting vape has set an important legal precedent for enforcing the Control of Smoking Products for Public Health Act (Act 852).
Jan.09 by 2FIRSTS.ai
PMI reports full-year 2025 results with net revenues of $40.6 billion and smoke-free net revenues were about $16.9 billion
PMI reports full-year 2025 results with net revenues of $40.6 billion and smoke-free net revenues were about $16.9 billion
Philip Morris International (PMI) released its Q4 and full-year 2025 results on February 6, 2026. PMI reported full-year net revenues of $40,648 million ($40.6 billion), reported diluted EPS of $7.26 and adjusted diluted EPS of $7.54. PMI said smoke-free net revenues were $16.9 billion and represented 41.5% of total net revenues, with smoke-free products available in 106 markets and over 43 million estimated adult consumers.
Feb.06 by 2FIRSTS.ai
Report Says Teen e-cigarette use on the rise, with majority of sales coming from disposable products
Report Says Teen e-cigarette use on the rise, with majority of sales coming from disposable products
Monitoring a Changing Tobacco Product Market in the United States is the second annual review from the Monitoring Tobacco Product Use project, analyzing retail scanner data from January 2019 to December 2024 and TEEN+ survey data.
Jan.07 by 2FIRSTS.ai
Malaysian Sabah GOF seizes e-cigarettes, vapes and e-liquids worth over  USD 156,333 in seven-district operation
Malaysian Sabah GOF seizes e-cigarettes, vapes and e-liquids worth over USD 156,333 in seven-district operation
In Sabah, Malaysia’s General Operations Force (GOF) seized thousands of e-cigarette devices, vapes and e-liquids worth more than RM635,000 and detained 23 people during a simultaneous integrated operation across seven districts.
Jan.19 by 2FIRSTS.ai
Azerbaijan’s Milli Majlis to hold public hearings on e-cigarette use in the 2026 spring session
Azerbaijan’s Milli Majlis to hold public hearings on e-cigarette use in the 2026 spring session
Azerbaijan’s Milli Majlis will hold public hearings regarding the use of e-cigarettes. The topic has been included in the 2026 spring session work plan of the Milli Majlis Committee on Agrarian Policy. During the spring session, the committee plans to convene a public hearing titled “Health is our goal: an end to e-cigarettes.”
Jan.23 by 2FIRSTS.ai
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
During the “Toxicological Profile” session at FDA’s Feb 10 PMTA roundtable, officials outlined the carcinogenicity tiering system and Excess Lifetime Cancer Risk (ELCR) framework used in ENDS reviews under the APPH standard. Small manufacturers questioned database transparency, exposure assumptions, and the existence of clear compliance benchmarks. FDA reiterated toxicological risk is assessed case by case within a broader population-level determination.
Feb.11